Therapeutic advances in immune checkpoint inhibitors for head and neck cancers

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses the clinical development of immune checkpoint inhibitors, including pembrolizumab, an anti-PD-1 antibody, and durvalumab, an anti-PD-L1 antibody, for the treatment of patients with head and neck cancer.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews